The company is pursuing drug development programs using two initial proprietary psilocin analogues: L-130, targeting neurological conditions such as severe anxiety, PTSD and brain traumas; and L ...

Leveraging his expertise in HPLC-MS and small molecule characterization, Dr. Ferguson and his team developed HPLC-MS and HPLC-UV methods for accurately quantifying psilocybin and psilocin.

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule th ...

Enveric Biosciences, Inc. (NASDAQ: ENVB) has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders. A ...

Vancouver, British Columbia--(Newsfile Corp. - July 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to ...

The result: Even a single dose of psilocin was sufficient to induce various changes in human nerve cells within a short ...

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule th ...

Scientists have found psychedelic drugs LSD and psilocin bind to a specific receptor in the brain to induce antidepressant effects – an advance that may lead to drugs that treat depression ...

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and ...

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has filed a provisional patent for the preparation and use of its proprietary and stable psilocin-related ...

As a “new chemical entity (NCE) psilocin prodrug,” EB-373 aims to treat anxiety disorder. Specifically, the upcoming patent is called “C4-Carbonothioate-Substituted Tryptamine Derivatives ...